Merck, Ridgeback to Deliver Additional 1.75 Million Courses of Oral Antiviral Covid-19 Drug to U.K.
22 Dezember 2021 - 01:00PM
Dow Jones News
By Kimberly Chin
Merck & Co. and Ridgeback Biotherapeutics LP said the U.K.
government has ordered an additional 1.75 million courses of
molnupiravir, its investigational oral antiviral Covid-19 drug.
The procurement agreement follows the U.K.'s previous order for
480,000 courses of the treatment.
The drug, which will also be known by its planned trademark of
Lagevrio, received a conditional marketing authorization in the
U.K. in early November to treat patients with mild to moderate
Covid-19 in adults who have at least one risk factor that can lead
to severe illness. The drug is currently available and used as a
treatment by patients in the U.K.
The U.S. Food and Drug Administration is reviewing an
emergency-use authorization for molnupiravir.
Separately, the U.K. ordered an additional 2.5 million courses
of Pfizer Inc.'s investigational oral antiviral Covid-19 drug,
which goes by the name Paxlovid, on top of its previous order of
250,000 courses. The drug is still awaiting regulatory
authorization and recommendation for use.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
December 22, 2021 06:45 ET (11:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2023 bis Mär 2024